Publication Name	World Journal of Experimental Medicine
Manuscript ID	3683
Country

Received	2013-05-14 12:06
Peer-Review Started	2013-05-14 16:12
First Decision by Editorial Office Director
Return for Revision	2013-06-18 13:02
Revised	2013-07-12 10:33
Publication Fee Transferred
Second Decision by Editor	2013-09-18 10:54
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-09-18 11:30
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-10-23 19:09
Publish the Manuscript Online	2013-11-20 17:44

ISSN	2220-315x (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Biochemistry & Molecular Biology
Manuscript Type	Original Articles
Article Title	Epigallocatechin-3-gallate suppresses transforming growth factor-beta signaling by interacting with the transforming growth factor-beta type Ⅱ receptor
Manuscript Source
All Author List	Masaki Tabuchi, Sumio Hayakawa, Eiko Honda, Kana Ooshima, Tatsuki Itoh, Koji Yoshida, Ah-Mee Park, Hideaki Higashino, Mamoru Isemura and Hiroshi Munakata
Funding Agency and Grant Number
Corresponding Author	Hiroshi Munakata, Professor, Department of Biochemistry, Kinki University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama 589-8511, Japan. munakata@med.kindai.ac.jp
Key Words	Epigallocatechin-3-gallate; Transforming growth factor-; Myofibroblast; -smooth muscle actin; Fibrosis
Core Tip	(-)-Epigallocatechin-3-gallate (EGCG) binds to transforming growth factor-β (TGF-?) type Ⅱ receptor (TGFRⅡ) and inhibits TGF-β action by interfering with the interaction between TGF-? and TGFRⅡ. Because TGF-? is considered to be the strongest inducer of tissue fibrosis, the obtained data from this investigation suggest that EGCG may be a new therapeutic agent for organ fibrosis.
Publish Date	2013-11-20 17:44
Citation	Tabuchi M, Hayakawa S, Honda E, Ooshima K, Itoh T, Yoshida K, Park AM, Higashino H, Isemura M, Munakata H. Epigallocatechin-3-gallate suppresses transforming growth factor-beta signaling by interacting with the transforming growth factor-beta type II receptor. World J Exp Med 2013; 3(4): 100-107
URL	http://www.wjgnet.com/2220-315X/full/v3/i4/100.htm
DOI	http://dx.doi.org/10.5493/wjem.v3.i4.100

Full Article (PDF)	WJEM-3-100.pdf
Manuscript File	3683-Review.doc
Answering Reviewers	3683-Answering reviewers.pdf
Copyright License Agreement	3683-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	3683-Language certificate.pdf
Peer-review Report	3683-Peer reviews.pdf
Scientific Editor Work List	3683-Scientific editor work list.doc